Skip to main content
SpringerLink
Log in

Interleukin-6 and its receptor: from bench to bedside

  • Review
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract

Interleukin-6 (IL-6) is an inflammatory cytokine with a well-documented role in inflammation and cancer. The cytokine binds to a membrane bound IL-6 receptor (IL-6R) and this complex associates with two molecules of the signal transducing protein gp130 thereby initiating intracellular signaling. While gp130 is present on most if not all cells of the body, the IL-6R is only present on some cells, mainly hepatocytes and several leukocytes. Cells, which only express gp130 and no IL-6R are refractory to IL-6 signals. We have shown earlier that the IL-6R can exist as a soluble protein generated by limited proteolysis of the membrane bound receptor or by translation from an alternatively spliced mRNA. This soluble IL-6R (sIL-6R) can bind the ligand IL-6 and the soluble complex of sIL-6R and IL-6 can bind to gp130 on cells which lack the membrane bound IL-6R and trigger gp130 signaling. We have named this process ‘trans-signaling’. We will review data, which clearly show that IL-6 uses classical signaling via the membrane bound receptor and trans-signaling via the soluble receptor in various physiological and pathophysiological situations. Furthermore, we have developed designer cytokines, which can specifically enhance or inhibit IL-6 trans-signaling. These designer cytokines have been shown to be extremely useful to in therapeutic applications ranging from the long-term culture of stem cells and enhancing liver regeneration up to the blockade of chronic inflammation and cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bazan JF (1990) Haemopoietic receptors and helical cytokines. Immunol Today 11:350–354

    Article  PubMed  CAS  Google Scholar 

  2. Hirano T, Kishimoto T (1992) Molecular biology and immunology of interleukin-6. Res Immunol 143:723–724

    Article  PubMed  CAS  Google Scholar 

  3. Grötzinger J, Kernebeck T, Kallen K-J, Rose-John S (1999) IL-6 type cytokine receptor complexes: hexamer or tetramer or both? Biol Chem 380:803–813

    Article  PubMed  Google Scholar 

  4. Grötzinger J, Kurapkat G, Wollmer A, Kalai M, Rose-John S (1997) The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins: Structure, Function, and Genetics 27:96–109

    Article  Google Scholar 

  5. Boulanger MJ, Chow D-C, .Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 a receptor/gp130 complex. Science 300:2101–2104

    Article  PubMed  CAS  Google Scholar 

  6. Grötzinger J (2002) Molecular mechanisms of cytokine receptor activation. Biochim Biophys Acta 1592:215–223

    Article  PubMed  Google Scholar 

  7. Schroers A, Hecht O, Kallen KJ, Pachta M, Rose-John S, Grötzinger J (2005) Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Prot Sci 14:783–790

    Article  CAS  Google Scholar 

  8. Rose-John S, Scheller J, Elson G, Jones S (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol (in press)

  9. Scheller J, Grötzinger J, Rose-John S (2006) Updating IL-6 classic- and trans-signaling. Signal Transduct (in press)

  10. Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signaling in chronic inflammation and cancer. Scand J Immunol 63:321–329

    Article  PubMed  CAS  Google Scholar 

  11. Taga T (1992) IL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130. Res Immunol 143:737–739

    Article  PubMed  CAS  Google Scholar 

  12. Müllberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23:473–480

    PubMed  Google Scholar 

  13. Müllberg J, Schooltink H, Stoyan T, Heinrich PC, Rose-John S (1992) Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun 189:794–800

    Article  PubMed  Google Scholar 

  14. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4:96–100

    Article  PubMed  CAS  Google Scholar 

  15. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 24:1945–1948

    PubMed  CAS  Google Scholar 

  16. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027

    PubMed  CAS  Google Scholar 

  17. Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300:281–290

    PubMed  CAS  Google Scholar 

  18. Peters M, Müller A, Rose-John S (1998) Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92:3495–3504

    PubMed  CAS  Google Scholar 

  19. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde KH, Rose-John S (1996) The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183:1399–1406

    Article  PubMed  CAS  Google Scholar 

  20. Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Dienes HP, Fattori E, Ciliberto G, Meyer zum Büschenfelde KH, Rose-John S (1997) Extramedullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J Exp Med 185:755–766

    Article  PubMed  CAS  Google Scholar 

  21. Schirmacher P, Peters M, Ciliberto G, Fattori E, Lotz J, Meyer zum Büschenfelde KH, Rose-John S (1998) Hepatocellular hyperplasia, plasmacytoma formation, and extracellular hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 153:639–648

    PubMed  CAS  Google Scholar 

  22. Peters M, Solem F, Schirmacher P, Rose-John S (2001) IL-6 and soluble IL-6R induce stem cell factor (SCF) and Flt-3 ligand expression in vivo and in vitro. Exp Hematol 29:146–155

    Article  PubMed  CAS  Google Scholar 

  23. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–1869

    Article  PubMed  CAS  Google Scholar 

  24. Staskus KA, Sun R, Miller G, Racz P, Jaslowski A, Metroka C, Brett-Smith H, Haase AT (1999) Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J Virol 73:4181–4187

    PubMed  CAS  Google Scholar 

  25. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186–1191

    Article  PubMed  CAS  Google Scholar 

  26. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM (1996) Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88:645–656

    PubMed  CAS  Google Scholar 

  27. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:1276–1280

    PubMed  CAS  Google Scholar 

  28. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT (1997) Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71:715–719

    PubMed  CAS  Google Scholar 

  29. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J et al (1997) Kaposi’s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851–1854

    Article  PubMed  CAS  Google Scholar 

  30. Berenson JR, Vescio RA (1999) HHV-8 is present in multiple myeloma patients. Blood 93:3157–3159

    PubMed  CAS  Google Scholar 

  31. Tarte K, Chang Y, Klein B (1999) Kaposi’s sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood 93:3159–3163

    PubMed  CAS  Google Scholar 

  32. Moore PS, Boshoff C, Weiss RA, Chang Y (1996) Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739–1744

    Article  PubMed  CAS  Google Scholar 

  33. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman Kien AE, Fleckenstein B (1997) Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71:839–842

    PubMed  CAS  Google Scholar 

  34. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M (1998) Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 91:1858–1863

    PubMed  CAS  Google Scholar 

  35. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA (1997) A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 272:19625–19631

    Article  PubMed  CAS  Google Scholar 

  36. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G (1999) Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034–4043

    PubMed  CAS  Google Scholar 

  37. Müllberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N, Heinz D, Galle PR, Klouche M, Rose-John S (2000) IL-6-receptor independent stimulation of human gp130 by viral IL-6. J Immunol 164:4672–4677

    PubMed  Google Scholar 

  38. Chow D-C, He X-L, Snow AL, Rose-John S, Garcia KC (2001) Structure of an extracellular gp130-cytokine receptor signalling complex. Science 291:2150–2155

    Article  PubMed  CAS  Google Scholar 

  39. Chatterjee M, Osborne J, Bestetti G, Yuan Chang Y, Moore PS (2002) Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298:1433–1435

    Article  CAS  Google Scholar 

  40. Rose-John S, Schooltink H, Lenz D, Hipp E, Dufhues G, Schmitz H, Schiel X, Hirano T, Kishimoto T, Heinrich PC (1990) Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem 190:79–83

    Article  PubMed  CAS  Google Scholar 

  41. Fischer M, Goldschmitt J, Peschel C, Kallen KJ, Brakenhoff JPJ, Wollmer A, Grötzinger J, Rose-John S (1997) A designer cytokine with high activity on human hematopoietic progenitor cells. Nat Biotechnol 15:142–145

    Article  PubMed  CAS  Google Scholar 

  42. Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ (2001) Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic cells. Proc Natl Acad Sci USA 98:1757–1762

    Article  PubMed  CAS  Google Scholar 

  43. Hacker C, Kirsch RD, Ju X-S, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380–386

    Article  PubMed  CAS  Google Scholar 

  44. Ju X-S, Hacker C, Madruga J, Kurz SM, Knespel S, Blendinger G, Rose-John S, Zenke M (2003) Differentiation of human dendritic cells fron hematopoietic progenitor cells assessed by transcriptional imaging with DNA microarrays. Eur J Cell Biol 82:75–86

    Article  PubMed  CAS  Google Scholar 

  45. Hieronymus T, Gust TC, Kirsch RD, Jorgas T, Blendinger G, Goncharenko M, Rose-John S, Müller A, Zenke M (2005) Progressive and controlled development of mouse dendritic cells from Flt3+ CD11b+ progenitors in vitro. J Immunol 174:2552–2562

    PubMed  CAS  Google Scholar 

  46. Humphrey RK, Beattie GM, Lopez AD, Bucay N, King CC, Firpo M, Rose-John S, Hayek A (2004) Maintenance of pluripotency in human embryonic stem cells is Stat3 independent. Stem Cells 22:522–530

    Article  PubMed  CAS  Google Scholar 

  47. Viswanathan S, Benatar T, Rose-John S, Lauffenburger D, Zandstra P (2002) Maintenance of ES cell pluripotentiality is regulated by the number and types of gp130-mediated signaling complexes. Stem Cells 20:119–138

    Article  PubMed  CAS  Google Scholar 

  48. Galun E, Zeira E, Shouval D, Pappo O, Peters M, Rose-John S (2000) Liver regeneration induced by a designed hIL-6/shIL-6R fusion protein reverses severe hepatocellular injury. FASEB J 14:1979–1987

    Article  PubMed  CAS  Google Scholar 

  49. Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Büschenfelde KH, Galle PR, Rose-John S (2000) Combined Interleukin-6 and soluble interleukin-6 receptor accelerates murine liver regeneration. Gastroenterol 119:1663–1671

    Article  CAS  Google Scholar 

  50. Hecht N, Pappo O, Shouval D, Rose-John S, Galun E, Axelrod JH (2001) Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol Therap 3:683–687

    Article  CAS  Google Scholar 

  51. März P, Cheng J-C, Gadient RA, Patterson P, Stoyan T, Otten U, Rose-John S (1998) Sympathetic Neurons can produce and respond to interleukin-6. Proc Natl Acad Sci USA 95:3251–3256

    Article  PubMed  Google Scholar 

  52. März P, Otten U, Rose-John S (1999a) Neuronal activities of IL-6 type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 11:2995–3004

    Article  Google Scholar 

  53. März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U (1999b) Role of interleukin-6 and soluble IL-6 receptor in region specific induction of astrocytic differentiation and neurotrophin expression. Glia 26:191–200

    Article  Google Scholar 

  54. Schäfer KH, Mestres P, März P, Rose-John S (1999) The IL-6/sIL-6R fusion protein promotes neurite outgrowth and neuronal survival in cultured enteric neurons. J Interferon Cytokine Res 19:527–532

    Article  PubMed  Google Scholar 

  55. Sun Y, März P, Otten U, Ge J, Rose-John S (2002) The effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons. Biochem Biophys Res Commun 295:532–539

    Article  PubMed  CAS  Google Scholar 

  56. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T (1993) Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82:1120–1126

    PubMed  CAS  Google Scholar 

  57. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem 268:160–167

    Article  PubMed  CAS  Google Scholar 

  58. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105–115

    Article  PubMed  CAS  Google Scholar 

  59. Rawat R, Rainey GJ, Thompson CD, Frazier-Jessen MR, Brown RT, Nordan RP (2000) Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6 independent phenotype by murine plasmacytomas and hybridomas. Blood 96:3514–3521

    PubMed  CAS  Google Scholar 

  60. Palmer J, Ernst M, Hammacher A, Hertzog PJ 2005 Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Prostate 62:282–289

    Article  PubMed  CAS  Google Scholar 

  61. Stuhlmann-Laeisz C, Lang S, Chalaris A, Sudarman E, Eichler J, Klingmüller U, Samuel M, Ernst M, Rose-John S, Scheller J (2006) Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine independent growth and blockade of differentiation of embryonic stem cells. Mol Biol Cell (in press)

  62. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:1139–1142

    Article  PubMed  CAS  Google Scholar 

  63. Croker BA, Krebs DL, Zhang J-G, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Förster I, Clausen BE, et al (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4:540–545

    Article  PubMed  CAS  Google Scholar 

  64. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10:739–743

    Article  PubMed  CAS  Google Scholar 

  65. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR (2006) Ciliary neurotrophic factor reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548

    Article  PubMed  CAS  Google Scholar 

  66. Feldmann M, Steinman L (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:612–619

    Article  PubMed  CAS  Google Scholar 

  67. Kallen K-J (2002) The role of transsignalling via the agonistic soluble IL-6 receptor. Biochim Biophys Acta 1592:323–343

    Article  PubMed  CAS  Google Scholar 

  68. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA (2003) Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171:3202–3209

    PubMed  CAS  Google Scholar 

  69. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95:8222–8226

    Article  PubMed  CAS  Google Scholar 

  70. Mihara M, Takagi N, Takeda Y, Ohsugi Y (1998) IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 112:397–402

    Article  PubMed  CAS  Google Scholar 

  71. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187:461–468

    Article  PubMed  CAS  Google Scholar 

  72. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–3150

    Article  PubMed  CAS  Google Scholar 

  73. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, et al (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterol 126:989–996

    Article  CAS  Google Scholar 

  74. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529

    Article  PubMed  CAS  Google Scholar 

  75. Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259–262

    PubMed  CAS  Google Scholar 

  76. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20:247–259

    Article  PubMed  CAS  Google Scholar 

  77. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O (1999) Interleukin-6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11:1057–1064

    Article  PubMed  CAS  Google Scholar 

  78. Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, Katada Y, Yoshizaki K, Suemura M, Kishimoto T (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 42:1635–1643

    Article  PubMed  CAS  Google Scholar 

  79. de Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB (2000) Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 157:2081–2089

    PubMed  Google Scholar 

  80. Kyo F, Futani H, Matsui K, Terada M, Adachi K, Nagata K, Sano H, Tateishi H, Tsutsui H, Nakanishi K (2005) Endogenous interleukin-6, but not tumor necrosis factor alpha, contributes to the development of toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum 52:2530–2540

    Article  PubMed  CAS  Google Scholar 

  81. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 54:158–168

    Article  PubMed  CAS  Google Scholar 

  82. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24:1510–1516

    PubMed  CAS  Google Scholar 

  83. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95

    Article  PubMed  CAS  Google Scholar 

  84. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P (1998) A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10:729–734

    Article  PubMed  CAS  Google Scholar 

  85. Robak T, Gladalska A, Stepien H, Robak E (1998) Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 7:347–353

    Article  PubMed  CAS  Google Scholar 

  86. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA (2001) Control of leukocyte infiltration during inflammation: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment. Immunity 14:705–714

    Article  PubMed  CAS  Google Scholar 

  87. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C et al (2000) Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of the antiapoptotic resistance of lamina propria T cells. Nat Med 6:583–588

    Article  PubMed  CAS  Google Scholar 

  88. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S et al (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501

    Article  PubMed  CAS  Google Scholar 

  89. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, El-Bdaoui H, Schmitt E, Bopp T, Kallen KJ, et al (2005a) The IL-6R alpha chain controls lung CD4+CD4+CD25+T regulatory cell development and function during allergic airway inflammation in vivo. J Clin Invest 115:313 –325

    Article  CAS  Google Scholar 

  90. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA (2005) IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102:9589–9594

    Article  PubMed  CAS  Google Scholar 

  91. Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, Yamamoto N, Ehrmann M, Williams AS, Rose-John S et al (2006) Baculovirus expression and functional characterisation of a recombinant human soluble gp130 isoform and its role in the regulation of L-6 trans-signaling. Arthritis Rheum 54:1662–1672

    Article  PubMed  CAS  Google Scholar 

  92. Doganci A, Sauer K, Karwot R, Finotto S (2005b) Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 28:257–270

    Article  CAS  Google Scholar 

  93. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036

    Article  PubMed  CAS  Google Scholar 

  94. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2623

    Article  PubMed  CAS  Google Scholar 

  95. Mitsuyama K, Tomiyasu N, Suzuki A, Takaki K, Takedatsu H, Masuda J, Yamasaki H, Matsumoto S, Tsuruta O, Toyonaga A, Sata M (2005) A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol 143:125–131

    Article  CAS  Google Scholar 

  96. Matthews V, Schuster B, Schütze S, Bußmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen K-J, Rose-John S (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278:38829–38839

    Article  PubMed  CAS  Google Scholar 

  97. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF (2005) IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220

    PubMed  CAS  Google Scholar 

  98. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769

    Article  PubMed  CAS  Google Scholar 

  99. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636

    PubMed  CAS  Google Scholar 

  100. Hochepied T, Van Molle W, Bergeri FG, Baumann H, Libert C (2000) Involvement of the acute phase protein a1-acid glycoprotein in nonspecific resistance to a lethal gram-negative infection. J Biol Chem 275:14903–14909

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Biochemie, Christian-Albrechts-Universität zu Kiel, Olshausenstr 40, 24098, Kiel, Germany

    Jürgen Scheller & Stefan Rose-John

Authors
  1. Jürgen Scheller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Rose-John
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Rose-John.

Additional information

There are inclusions in this text from a number of different articles, which are cited in the reference section.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheller, J., Rose-John, S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 195, 173–183 (2006). https://doi.org/10.1007/s00430-006-0019-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-006-0019-9

Keywords

Search

Navigation